Rheavita
2 known investors
RheaVita develops the RheaLyo continuous, controlled GMP-ready freeze-drying (lyophilization) technology for high-value biologics such as drugs and vaccines. Its systems, aimed at biopharmaceutical developers, support process development, scale-up tech transfer, and regulatory-compliant automation and documentation.
Investors · 2
Frequently asked questions
- What does Rheavita do?
- RheaVita develops the RheaLyo continuous, controlled GMP-ready freeze-drying (lyophilization) technology for high-value biologics such as drugs and vaccines. Its systems, aimed at biopharmaceutical developers, support process development, scale-up tech transfer, and regulatory-compliant automation and documentation.
- Who are Rheavita's investors?
- Rheavita's investors include Novalis Biotech, PMV.